This study was undertaken to evaulate the biological potency of two synthetic human growth hormone-releasing factors, hGRF (1-44)Nil 2 and hGRF (1-29)NH2, on growth hormone (GH) release in young dairy heifers (n = 10) and pigs (n = 10). in each species, the GH response to an iv injection (0, .067, .2, .6 and 1.8 nmol'kg -1 body weight) of each peptide was evaluated in a double 5 • 5 Latin square design. In each square, there were five animals injected with either hGRF (1--44)NH 2 or hGRF (1--29)NH 2 . Main effects were doses (n = 5) of hGRF and days (n = 5) of injection. In both species, data indicated that hGRF (1--44)NH 2 and hGRF (1-29)Ntt~ equally stimulate GH secretion at all doses. In dairy heifers, average peak concentrations (81.7, 94.7, 84.5 and 93.7 ng'm1-1 vs 91.5, 81.0, 94.3 and 91.6 ng-m1-1 ) and area under the GH response curve (3,661, 4,541, 7,196 and 6,788 ng'ml -x "min vs 3,000, 3,982, 5,639 and 6,724 ng'ml -t .min)
Introduction
Growth hormone-releasing factor (GRF) was recently isolated and sequenced by and Rivier et al. (1982) lecules with GRF activity: hpGRF (1-37)OH, hpGRF (1-40)OH and hpGRF (1--44)NH2. Eventually, hGRF (1--44)NH2 from human hypothalami was characterized and found to be identical to hpGRF (1--44)NH2 . Chemical synthesis of hGRF (1-44)NH2 and fragments thereof can be achieved by solid phase peptide synthesis (Merrifield, 1963) . Biological activities of amidated synthetic preparations were tested in a monolayer culture system of normal rat anterior pituitary cells . Human GRF (1-44)NH2 was the most potent peptide tested , whereas hGRF (1--29)NH2 retained, on a molar basis, 73 to 98% of the hGRF (1--44)NH2 biological activity (P. Brazeau, unpublished data) . In cattle, intravenous injection of hGRF (1--44)NH2 induced growth hormone (GH) release in young bulls (Enright et al., 1984; Hodate et al., 1984b) , female calves (Hodate et al., 1984a) , steers (Moseley et al., 996 J. Anim. Sci. 1987 Sci. .65:996-1005 1984) and lactating cows (Baile et al., 1985; Lapierre et al., 1985; Enright et al., 1986) . In swine, the first 29 amino acids of porcine (p) GRF (1--44)NH 2 are identical to human GRF (1--29)NH2 (Bohlen et al., 1983) . Porcine GRF (1-29)NH2 can stimulate pGH release in anesthetized and conscious pigs (Kraft et al., 1985) . However, to our knowledge, the relative potency of hGRF (1--44)NH2 and (1-29)NH2 on GH release in cattle and swine is unknown. Therefore, the objective of this study was to evaluate the potency of hGRF (1--44)NH2 and (1--29)NH2 on GH release in young dairy heifers and pigs.
Materials and Methods
Cannulation. Blood catheters 7 (SLV 105--18) were inserted 3 d or on the day prior to injection with hGRF peptides into a jugular vein of each pig and heifer, respectively. Cannulation of heifers was performed on restrained animals. Cannulation of pigs was performed under general anesthesia induced with Hypnodil s (10 mg-kg -1 body weight) injected ip 15 min after im injection of Stresnil 9 (2.2 mg-kg-1 body weight).
Cannulas were used for iv injection and withdrawal of blood samples. Cannulas were flushed with 3.5% sodium citrate after collection of each sample and maintained filled between blood sampling periods with either 3.5% sodium citrate (heifers) or heparin (20 IU.m1-1 ; pigs).
GRF. In both experiments, hGRF
(1--44)NH21~ (molecular weight of 5,040.4) and hGRF (1--29)NH211 (molecular weight of 3,358.4) were synthesized by solid phase methodology (Merrifield, 1963) and purified by high pressure liquid chromatography. Purity (homogeneity) of hGRF (1--44)NH2 and (1-29)NH2 was 86 and 95%, respectively, with a peptide content of 93.4 and 99%. Both peptides were dissolved in HC1 (.1N), neutralized in NaOH (.1N) and stock solutions were diluted in phosphate buffer (.1M, pH 7.4). Doses injected (.1 to .2 ml of stock solution) were diluted prior to injection with 5 to 7 ml of saline (.9%).
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Exp. I: Effects of bGRF in Young Heifers.
Ten Holstein heifers, aged 15 to 23 wk at the beginning of experiment, were housed in a heated, ventilated barn. Heifers were fed ad libitum alfalfa silage and hay supplemented with 2.5 kg of a complete pelleted concentrate and had free access to water. Animals were subjected to natural daily change of photoperiod. Injections were administered between March 4 to 8, 1985.
The GH response to an iv dose of both hGRF peptides was evaluated statistically in a double 5 • 5 Latin square design. In each square, there were five animals injected with either hGRF (1--44)NH~ or hGRF (1--29)NH2. Main effects were doses (n = 5) of hGRF injected and days (n = 5) of injection. Heifers were paired between square according to body weight (+ 3 kg). Each pair was kept together in pens throughout the treatment period. Heifers were restrained during sampling periods and had free access to water and feed. Each heifer received daily for five consecutive days a single, rapid injection of either hGRF (1--44)NH2 (five heifers averaging 128.3 kg body weight) or hGRF (1--29)NH2 (five heifers averaging 129.6 kg body weight). Doses tested were O, .067, .2, .6 and 1.8 nmol.kg -1 body weight. A dose of.2 nmol.kg -1 body weight of hGRF (1--44)NH2 and hGRF (1--29)NH2 was equivalent to 1 and .66 /lg.kg -1 body weight, respectively. Blood samples were withdrawn at-60,-30,-15, -10, 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180 and 240 min around the time of injection. Time of injection was 1300 every day. Part of these results have been reported by Petitclerc et al. (1986) , using protein A instead of second antibody precipitation. Identical treatment effects were observed even though GH concentrations were much lower then those reported in this paper.
Exp. 2: Effects of bGRF in Pigs.
Ten crossbred pigs, 10 to 12 wk of age at the beginning of experiment, were housed in a heated, ventilated barn. Pigs were maintained alone in separate pens and fed ad libitum a complete pelleted diet and had free access to water. Animals were subjected to natural daily change of photoperiod. Injections were administered between March 25 to 29, 1985. The GH response to an iv dose of both GRF peptides was evaluated statistically in a double 5 • 5 Latin square as described in Exp. 1. After a few days of training, pigs were calm and needed only to be cornered in their pen for blood sampling. Pigs injected with hGRF (1-44)NH2 (n = 5) averaged 28.9 kg body weight as did those injected with hGRF (1-29)NH2 (n = 5). Doses tested were 0, .067, .2, .6 and 1.8 nmol.kg -1 body weight. Blood samples were withdrawn as described in Exp. 1. Time of injection was 1200 every day.
Radioimmunoassay. Blood samples were allowed to clot for 2 to 6 h at approximately 20 C, then stored at 4 C until the next day when they were centrifuged at 2,000 x g for 20 to 30 rain. Sera were decanted and stored at -20 C until assayed for hGRF (1--44)NH2 concentrations and bovine or porcine GH concentrations by radioimmunoassay procedure.
Serum bovine (b) and porcine (p) GH concentrations were quantified using an ovine GH antibody raised in a Rhesus monkey 12. Antibodies were used in bGH and pGH assays at 1:150,000 and 1:100,000 final antibody dilution, respectively. Reference standards for bGH and pGH were N1H-GH-B17 and RASG14276-A-113 . Briefly, 100/al of standard in phosphate buffer (.01M; pH 7.4) in .14M NaC1 (PBS) containing 7.5% bovine serum albumin or sample, 100/al of 12s I-GH (approximately 12,000 cpm) and 400 /al of first antibody diluted in PBS-EDTA (.05M) were incubated at room temperature for 18 to 24 h. Then, 100/al of goat antimonkey gamma globulin (1:10 dilution in PBS-EDTA (.05M) containing 2.5% monkey serum) was added, mixed and let stand for 1 h before centrifugation for 30 min at 2,000 x g. Supernatants were decanted and pellets counted using a Micromedic auto gamma counter. The interand intra-assay coefficients of variation for pooled serum were 6.4 and 11.8%, respectively.
Human GRF (1-44)NH2 was assayed by a double antibody procedure as described by Brazeau et al. (1984) . First antibody was raised in rabbits against hGRF (1-40)OH and has been validated for use with bovine and porcine serum. This antibody did not cross-react with hGRF (1-29)NH2.
Statistical Analysis. Data were analyzed by the least-squares method of analysis of variance according to the General Linear Models procedure in the Statistical Analysis System (Barr et al., 1979) . Polynomial response curves were used to describe time trends. The following model was used to analyze the data: Yijkl =/a + t2From Dr. D. DesCotes, Sanofi, Montpellier, France.
13 From Dr. T. Mowles, Hoffman LaRoche, Nutley, NJ.
Gi + A(i)j + Ck + GCik + D1 + GDil + e(i)jkl, where g = overall mean; G i = fixed effect of the i th square [hGRF (1--44)NH2 vs hGRF (1--29)NH21; A(i)j = error a (animals nested within each square); C k = fixed effect of the k th dose of hGRF; GCik = interaction between hGRF peptides and dose; D1 = fixed effect of the I th day of injection; GDil = interaction between type of hGRF and days of injection and e(i)jkl = random error. Area under the curve (AUC) was calculated using the trapezoidal method after excluding area under basal level before injection. Peak concentration was the highest concentration attained after injection. Orthogonal polynomial contrasts were used to test dose effect of hGRF peptides on peak GH concentrations and AUC (Gill, 1978) . 
Exp. 2. In control pigs, basal concentrations
of hGRF (1--44)NH2-1ike immunoreactivity averaged 871 pg.m1-1 (figure 4) and basal pGH bNo interaction (P>.05) between hGRF peptides and dose on peak GH concentrations and AUC.
CLinear (P<.O01) effect for peak GH concentrations. Linear (P<.O01) effect and a tendency (P<.I) for a quadratic component for AUC. There was no (P>.05) interaction between square and dose effects concerning peak GH concentrations and A UC. Human GRF (1--44)NH2 and hGRF (1--29)NH2 increased linearly (P<.001) GH secretion as measured by peak concentrations attained after injection (table  3) . However, the amount of pGH release as measured by area under the pGH curve increased linearly (P<.001) and quadratically (P<.I) with doses of both hGRF (1--44)NH 2 and (1--29)NH 2 peptides (table 3) .
Pearson correlation coefficients between dose of hGRF (1--44)NH2 and peak on AUC of serum hGRF (1--44)NH2 response was .82 and .93 (P<.O01), respectively (table 4). Pearson correlation coefficients between dose of hGRF (1--44) NH2 and peak or AUC of serum bGH response were .44 (P<.05) and .50 (P<.01), respectively. However, the correlation coefficient between peak of hGRF (1--44)NH2 and AUC of bGH response (.22) was not significant. In addition, there was no correlation (.28) between AUC of hGRF (1--44)NH2 and AUC of bGH response.
Discussion
Our results indicate that the intrinsic biological activity of hGRF on GH release in heifers and pigs resides within the first 29 amino acids of the molecule. In rats, pigs, sheep and steers in vivo, the 1-29 amidated sequence retained much of the GH releasing activity of longer peptides (Wehrenberg and Ling, 1983; A1-Raheem et al., 1984 A1-Raheem et al., , 1986 Lance et al., 1984; Hart et al., 1985; Spires et al., 1985) . However, shorter peptides, such as (1-10)NH2, (1--24)NH 2 and (1--28)NHz have much-reduced biological activity. In lactating cows, McCutcheon et al. (1984) observed stimulation of bGH release with hGRF (1--29)NH2 but a marginal response with hGRF (1-25)NH2. However, they did not compare their results with hGRF (1-44)NH2. In sheep, Hart et al. (1985) observed no significant difference in GH response among hpGRF-44-NH2, hpGRF-40-OH, hpGRF (1--29)NH2 and rGRF (1--29)NH2. In heifers and pigs, our results demonstrate that hGRF (1-44) NH2 and hGRF (1--29)NHz can equally stimulate GH secretion. Indeed, average peak concentrations and area under the GH curve at all doses were not significantly different between peptides. These data are in agreement with in vitro studies done in our laboratory. In fact, in a monolayer culture system of normal rat anterior pituitary cells, the (1--29)NH2 fragment of hGRF (1--44)NH2 and rat GRF (1--43)OH retained on a molar basis 85.2 and 98.9% of the rat GH releasing activity (Brazeau, unpublished data) . Even though the 44 amino acid peptide is well within the range for rapid solid phase synthesis, it will be much more cost efficient to work with as short a sequence as possible while maintaining biological activity. Thus, there would be a tremendous advantage in using the (1--29)NH2 fragment of hGRF (1--44)NH2 to stimulate GH secretion in dairy cattle and swine.
A biphasic release of bGH was observed in steers administered 1,000 /lg of hpGRF (1--44)NH2 (Moseley et al., 1984) and in dairy cows administered 2,000 pg of hGRF (1--29)NH2 (McCutcheon et al., 1984) . In our study, we observed a similar response at the highest dose of both hGRF (1-44)NH2 and hGRF (1--29)NH2 in dairy heifers. This seco.M release occurred after hGRF (1--44)NH2 had disappeared from blood circulation. The release of endogenous GRF and(or) a reduction ill endogenous somatostatin secretion after the first surge of GH release are probably responsible for this biphasic pattern of GH secretion.
The GH response to hGRF stimulation was less predictable in pigs than in dairy heifers. Often, we observed in pigs a delayed response occurring between 40 to 120 min post-injection. There was also, at the two highest doses, some animals showing peak responses up to 150 to 180 ng.mI -l. In addition, the correlation coefficients between dose of hGRF (1--44) NH2 injected and peak or AUC of GH response were lower and not as significant in pigs as compared with dairy heifers. Furthermore, the correlation coefficient between the AUC of hGRF (1--44)NH2 and peak of GH response was not significant in pigs, whereas the same coefficient was twice as large (P<.05) in dairy heifers. The episodic refractoriness of endogenous GH release due to somatostatin secretion might influence more significantly the hGRF-induced GH release in pigs as compared with dairy heifers.
In conclusion, utilization of growth hormone-releasing factors offers tremendous opportunities to improve growth and lactation in pigs and dairy cattle and perhaps other farm animals. However, more research is needed to develop long-acting preparations, as well as more potent analogues of GRF. Potential interaction of GRF with other releasing or inhibiting factors should be investigated.
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